VistaGen Therapeutics Inc (VTGN)

[Fress]

This last week VistaGen Therapeutics initiated by Jefferies Financial Group Inc. at buy. $6.00 PT within 12 months they know their research well. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. In this case, Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B.

Took my GME profits from yesterday and today and added more VTGN
another 77k shares added yesterday.



A disruptive Depression and anxiety next generation meds low side effects and fast acting. This is now my largest holding Thanks for the cheapies 2.24-2.26 filled today much appreciated. Phase 3 multiple Phase 2'a enough cash to fund SAD Social anxiety Disorder across the finish line. 16 drug indications in their pipeline. They will get bought out most likely Like Biogen bought SAGE 1/3'1/2 the population suffering from Depression and anxiety.

Biogen Bets $1.5 Billion on Sage Therapeutics' Drug for Depressive Disorders.
https://www.biospace.com/article/biogen-makes-1-5-billion-bet-on-depression-treatments-under-development-by-sage-therapeutics/

COVID-19 disrupting mental health services in most countries, WHO survey World Mental Health Day to highlight urgent need to increase investment in chronically underfunded sector..

The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey. The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.


https://www.who.int/news/item/05-10-2020-covid-19-disrupting-mental-health-services-in-most-countries-who-survey

VTGN Pipeline:
https://www.vistagen.com/pipeline

VTGN Biz presentation:
https://d1io3yog0oux5.cloudfront.net/_78f83b9b022497768da4a497c4d9e5b2/vistagen/db/241/816/pdf/VistaGen+Corporate+Presentation+Website+2020_11_16+250pm+PT.pdf

VTGN Twitter:
https://twitter.com/VistaGen?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Anxiety depression peers:
$CMPS 2 billion market cap early clinical trials. 190 million cash
$MMEDF 1.2 billion market cap.
$SAGE 3 Billion market cap bought out a few weeks ago for deperession anxiety pipeline.
$VTGN 357 million market cap Phase 3 ready. (nasdaq)
115 million in cash

Depression and anxiety one of the most sought after sector in biotech large population of people in the world are depressed.


93% increase in people participating in anxiety screenings, according to Mental Health America.
Study finds Colorado has 31% average rate of depression and anxiety.
https://www.denverpost.com/2021/02/18/mental-health-colorado-pandemic-anxiety-depression/


$VTGN